Taniguchi Kohei, Sakai Miku, Sugito Nobuhiko, Kuranaga Yuki, Kumazaki Minami, Shinohara Haruka, Ueda Hiroshi, Futamura Manabu, Yoshida Kazuhiro, Uchiyama Kazuhisa, Akao Yukihiro
United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan; Department of General and Gastroenterological Surgery, Osaka Medical College, Daigaku-machi, Takatsuki, Osaka 569-8686, Japan.
United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan.
Biochem Biophys Res Commun. 2016 Apr 22;473(1):174-180. doi: 10.1016/j.bbrc.2016.03.074. Epub 2016 Mar 21.
Resistance to chemotherapy is a crucial problem in the clinical situation. To overcome this issue, many mechanisms of chemoresistance have been elucidated so far. However, this problem still has not been solved completely. In this study, we investigated the mechanism of chemoresistance from the view of cancer metabolism-related genes, especially focusing on the expression profile of pyruvate kinase muscle (PKM) isoforms, which are rate-limiting enzymes in cancer-specific metabolism (Warburg effect). Herein, we showed that PKM1, which promotes oxidative phosphorylation (OXPHOS), was commonly up-regulated in various chemoresistant cells. To clarify the functions of PKM1 in chemoresistance, we investigated effects of PKM1 expression in DLD-1 parental, 5-FU-resistant and oxaliplatin-resistant DLD-1 cells. The overexpression of PKM1 resulted in resistance of the parental cells to 5-FU and oxaliplatin. Moreover, gene-silencing of PKM1 induced apoptosis in these cells including the resistant cells by causing a decrease in the mitochondrial membrane potential. Furthermore, combination therapy using 5-FU or oxaliplatin with siR-PKM1 was also effective against the resistant cells. Our findings should lead to the development of new agents that can cancel the chemoresistance from the view of cancer energy metabolism.
化疗耐药是临床治疗中的一个关键问题。为克服这一问题,目前已阐明了许多化疗耐药机制。然而,这个问题仍未得到彻底解决。在本研究中,我们从癌症代谢相关基因的角度研究了化疗耐药机制,尤其关注丙酮酸激酶M2型(PKM)亚型的表达谱,其是癌症特异性代谢(瓦伯格效应)中的限速酶。在此,我们发现促进氧化磷酸化(OXPHOS)的PKM1在各种耐药细胞中普遍上调。为阐明PKM1在化疗耐药中的作用,我们研究了PKM1在DLD-1亲代细胞、5-氟尿嘧啶耐药和奥沙利铂耐药的DLD-1细胞中的表达影响。PKM1的过表达导致亲代细胞对5-氟尿嘧啶和奥沙利铂产生耐药性。此外,PKM1基因沉默通过降低线粒体膜电位诱导这些细胞(包括耐药细胞)凋亡。此外,使用5-氟尿嘧啶或奥沙利铂与siR-PKM1的联合治疗对耐药细胞也有效。我们的研究结果应能推动从癌症能量代谢角度开发可消除化疗耐药性的新型药物。